Skip to Content

Geneva Capital Management LLC sells 13,727 Catalent, Inc. shares (NYSE:CTLT)

Geneva Capital Management LLC sells 13,727 Catalent, Inc. shares (NYSE:CTLT)

Geneva Capital Management LLC sold 5.1% of its stake in Catalent Inc. (NYSE: CTLT) during the third quarter, as stated in the most recent report that the company submitted to the Securities and Exchange Commission (SEC). (SEC). Following the previous quarter’s transaction, the institutional investor now has 254,404 shares of the company’s stock in their possession. This brings the total number of shares owned by the investor to 254,404. In the most recent report that Geneva Capital Management LLC provided to the Securities and Exchange Commission, the company stated that it owned 0.14% of Catalent, which at the time had a value of $18,409,000. (SEC).

During the past few months, several institutional investors have modified the interests that they currently hold in the company. During the second quarter of this fiscal year, Price T. Rowe Associates Inc. (MD) increased the percentage of ownership of Catalent that it held by 9.9%. Price T. Rowe Associates Inc. (MD) now owns 22,303,561 shares of the company, which are currently valued at $2,392,949,000 following the purchase of an additional 2,011,520 shares during the most recent quarter. This brings the total number of shares owned by the company to 22,303,561. During the second quarter, Artisan Partners Limited Partnership acquired an additional 20.4% of the total number of shares of Catalent common stock. Artisan Partners Limited Partnership now has 5,232,772 shares after purchasing an additional 887,520 in the most recent quarter. The value of Artisan Partners Limited Partnership’s holdings in the business at the moment is $561,424,000. During the second quarter, approximately 54,808,000 dollars were spent by Samlyn Capital LLC to acquire a greater percentage of ownership in Catalent. During the first three months of 2018, Vanguard Group Inc. increased the amount of Catalent stock that is owned by 2.7%, bringing the total amount of stock it owned to a total of Vanguard Group Inc. now directly owns 18,971,342 shares in the company, which have a value of $2,103,921,000 thanks to the purchase of 492,071 additional shares in the company during the preceding quarter. These shares were purchased for a total of $2,103,921,000.

Last but not least, during the second quarter, Eminence Capital LP increased the proportion of Catalent owned by 48.6%. After making additional purchases totaling 342,616 shares during the most recent fiscal quarter, Eminence Capital LP now has 1,047,329 shares of the company’s stock in its possession. The aggregate value of these shares is 112 368 000 dollars. At the moment, institutions’ portfolios comprise 99.38% of the total number of shares of the company.

Most of the attention that recent analyst reports have focused on is being paid to CTLT. Bank of America decreased its price target for Catalent from $125.00 to $60.00. It downgraded the company from a “buy” rating to a “neutral” rating in a report published on Wednesday, November 2. In addition, they changed their recommendation for Catalent from “buy” to “neutral,” reflecting their lack of interest in the stock. Catalent’s stock received a grade of “c+” from TheStreet on October 28, one day after the company’s rating was lowered from “b-” to “c+.” In a research note published on November 2, Barclays lowered its “overweight” rating on Catalent and dropped its price objective for the company from $105.00 to $62.00. Both of these moves were made about the company’s stock. KeyCorp published the research note on Catalent on November 2, stating that the company had assigned an “overweight” rating to the company’s stock while simultaneously decreasing their price objective from $125.00 to $85.00. The research note also stated that the company’s price objective had decreased from $125.00 to $85.00.

Last but not least, in a research note published on Thursday, November 3, Morgan Stanley announced that the price objective they had set for shares of Catalent had been decreased from $120.00 to $81.00 while maintaining an “overweight” rating on the stock. One of the equity research analysts has suggested that investors sell the stock, while another three believe that investors should continue to hold onto it, and the remaining five believe that investors should buy it. According to information from Bloomberg.com, the current rating for Catalent is “Hold,” and the website reports that the average price target is $92.80. Both of these pieces of information can be found on the website.

On a related note, On October 31, Senior Vice President Michael J. Grippo made a transaction in which he sold 2,451 shares of company stock. This follows on the heels of other events that have taken place recently. The shares were acquired for a total cost of $161,349.33, which works out to a price of $65.83 per share on an average basis. The senior vice president owns 17,792 shares of the company’s stock, and the combined value of those shares is $1,171,247.36 at present. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. You will have the opportunity to acquire additional information regarding the transaction. Michael J. Grippo, Senior Vice President of the company, sold 2,451 shares of the company’s stock on October 31. This piece of news was included with the other updates about Catalent. The shares were acquired for a total cost of $161,349.33, which works out to a price of $65.83 per share on an average basis.

After the deal’s completion, the senior vice president has direct ownership of 17,792 company shares, which have a value of $1,171,247.36. You can find a document that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website. Manja Boerman, an employee of the company who is considered an insider, sold 780 shares of the company’s stock on Monday, December 5. Additionally, Manja Boerman was involved in the sale of company shares. It was determined that the shares were sold for $51.70 per share, which resulted in a total sale volume of $40,326.00. This was determined by determining the average price at which the shares were sold. After the completion of the transaction, the company insider now possesses 15,860 shares of the company, which have a total value of $819,962. Disclosures that are related to the sale might be found in this section of the website. The total number of shares currently in circulation represents a total ownership stake of 0.58% by company insiders.

NYSE: CTLT began its trading session on Tuesday at $49.08 per share. The ratio of the current ratio to the quick ratio is 2.08, while the ratio of the current ratio to the quick ratio is 2.86. The ratio of debt to equity is 0.87. A price-to-earnings ratio of 20.97, a price-to-earnings-growth ratio of 3.39, and a beta value of 1.24 are all characteristics of the stock in question. The company’s total value, as represented by its market capitalization, is $8.83 billion. The company’s moving average over the past 50 days is $45.72, and its moving average over the past 200 days is $74.54. During the last twelve months, the share price of Catalent, Inc. has ranged from $40.69 to $115.33 per share.

The most recent quarterly earnings report for Catalent, traded on the New York Stock Exchange under the symbol CTLT, was released on November 1. The company reported a quarterly profit of $0.25 per share, which was significantly lower than the consensus estimate of $0.49 per share among financial analysts, which was $0.24. Catalent achieved a return on equity of 12.55%, and the net margin for the company was 8.83%. Despite predictions made by analysts that the company would bring in $1.06 billion during the quarter, the actual revenue that the company was able to bring in was only $1.02 billion. According to the research carried out by equity analysts, it is anticipated that Catalent, Inc. will have earnings of $2.93 per share in 2018.

Research and manufacturing solutions for the pharmaceutical industry, the biologics industry based on proteins, the cell and gene therapy industry, and the consumer health goods industry are all areas of focus for Catalent, Inc. and its affiliated companies, which conduct their operations all over the world. The Softgel and Oral Technologies section offers formulation, development, and production services for soft capsules for a wide range of client products, including prescription drugs, over-the-counter medicines, dietary supplements, unit-dose cosmetics, and animal health medical preparations. These services are provided for soft capsules used in softgels and oral technologies. These services are adaptable enough to work with a wide range of client products.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *